Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department

• DOI: 10.20452/pamw.3452
• Publication Date: 2016-06-30T15:40:44Z
• Authors: Michał M. Farkowski; Aleksander Maciąg; Małgorzata Żurawska; Mariusz Pytkowski; Ilona Kowalik; Jacek Woźniak; Maciej Sterliński; Hanna Szwed
• Keywords: Propafenone; Clinical endpoint

INTRODUCTION Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion short‑duration atrial fibrillation (AF). However, there are no data on comparison antiarrhythmic drugs listed clinical guidelines. OBJECTIVES The aim study was to assess comparative antazoline‑based propafenone‑based strategies AF performed our emergency department. PATIENTS AND METHODS We conducted a retrospective case‑control based analysis medical records patients undergoing with intravenous or propafenone at department years 2008-2012. primary endpoint successful AF. hospitalization due adverse effects treatment. RESULTS analyzed 432 cases cardioversion. mean age 68.9 ±9.8 years; 65% were male; 90% had history Antazoline administered 334 times propafenone-98 times. dose 172 ±65 mg, while all group received drug fixed 70 mg (1 vial). Cardioversion 239 (71.6%) propafenone-in 54 (55.1%) (relative risk [RR], 1.30; 95% confidence interval [CI], 1.07-1.57). rate treatment low similar between groups: 10 (3.0%) for 4 (4.1%) (RR, 0.73; CI, 0.23-2.27). CONCLUSIONS strategy more effective safer